Form 4: Enliven COO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock for approximately $20.10 per share as part of a pre-arranged trading plan.
Summary
- Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
- The transaction involved the disposition of 6,667 shares of Enliven Therapeutics common stock.
- The shares were sold on October 7, 2025, at a weighted average price of $20.0979 per share.
- The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
- Following the reported transaction, Anish Patel beneficially owns 276,641 shares indirectly through The Patel / Dong Family Trust Dated August 24, 2017, for which he serves as trustee.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly negative. While an insider sale can be perceived negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse non-public information. It's likely a planned liquidity event.
Negatives
- An insider sale, even if pre-planned, can sometimes be perceived by the market as a lack of confidence or a move to diversify holdings, potentially leading to negative sentiment.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a standard insider transaction report and does not provide information to analyze broader industry trends or competitor activities. It reflects an individual executive's personal financial planning.
Related Party Transactions
- The shares beneficially owned following the transaction are held by The Patel / Dong Family Trust, for which the Reporting Person, Anish Patel, serves as trustee. The sales were also effected by this trust.
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan suggests it's a routine, pre-planned event rather than a reaction to new company developments.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person and The Patel / Dong Family Trust. |
| 10/07/2025 | Date of the reported transaction (sale of common stock). |
| 10/09/2025 | Date the Form 4 filing was signed. |
Keywords
Enliven Therapeutics, ELVN, Anish Patel, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Officer Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.